Windlas Biotech Reports Stable Financial Performance Amid Concerns Over Non-Operating Income Sustainability
Windlas Biotech has reported stable financial results for the quarter ending March 2025, achieving record net sales of Rs 202.71 crore and an operating profit of Rs 25.56 crore. However, the increase in non-operating income raises concerns about its sustainability in the future.
Windlas Biotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results, declared on May 22, 2025, indicate a stable financial performance during this period. However, there has been an adjustment in evaluation, with the stock's score reflecting a shift from 6 to 5 over the past three months.The financial data reveals that Windlas Biotech achieved its highest quarterly net sales at Rs 202.71 crore, marking consistent growth each quarter over the last five quarters. Additionally, the operating profit (PBDIT) reached Rs 25.56 crore, also the highest in the same timeframe, suggesting a positive near-term trend in operational efficiency.
Conversely, the company reported its highest non-operating income at Rs 4.94 crore in the last five quarters. This increase, stemming from non-business activities, raises questions about its sustainability moving forward.
Overall, Windlas Biotech's recent financial results highlight both strengths in sales and operating profit, alongside concerns regarding the sustainability of non-operating income.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
